Cutera® Launches New Residency Program to Shape the Future of Dermatology

 A Collaboration Designed to Advance Clinical Education, Innovation, and Research for Dermatologists

BRISBANE, Calif., Sept. 24, 2025 /PRNewswire/ -- CUTERA, INC., a leading provider of aesthetic and dermatological solutions, announces the launch of its Cutera Residency Program, a new program designed to expand access to AviClear^®, the first FDA-cleared 1726 nm laser for the long-term treatment of mild, moderate, and severe acne, into dermatology training programs across North America.

This new program aims to support acne care innovation, research, and education by integrating AviClear into the clinical curriculum of leading academic institutions. By incorporating AviClear directly into residency programs, Cutera is equipping future dermatologists with the tools and technology they need to expand their armamentarium.

"Our goal is to empower the next generation of dermatologists through education and innovation," said Taylor Harris, CEO of Cutera Inc. "By introducing AviClear into residency programs, we're advancing clinical training while reinforcing our commitment to pioneering solutions that shape the future of dermatology and improve lives."

The program establishes a 24-month partnership that includes technology integration and structured clinical training. Alongside education, it creates collaboration opportunities on publications, research, podium presentations, and exploration of new clinical indications. Looking ahead, the program also creates pathways to Cutera's broader technology portfolio, ensuring participants gain exposure to a wide spectrum of innovations in dermatology and aesthetics.

"Residents will now have early access to cutting-edge technology like AviClear, giving them hands-on experience with the future of acne care," said Ashish C. Bhatia, M.D., FAAD, Co-Director of Dermatologic, Laser and Cosmetic Surgery at Oak Dermatology. "At the same time, this partnership opens the door to exciting new research opportunities into sebaceous-based conditions such as sebaceous hyperplasia and hidradenitis suppurativa, expanding what's possible in dermatologic care."

Since the launch of AviClear, thousands of patient treatments have been performed world-wide, giving practitioners real-world evidence of its safety, effectiveness, and durability. Beyond acne, Cutera's clinical research team is actively studying AviClear in a range of new indications tied to the sebaceous gland, including sebaceous hyperplasia, hidradenitis suppurativa, oily skin, and pore size, with additional exploratory research underway. These efforts highlight both the versatility and power of the 1726 nm wavelength and Cutera's commitment to advancing innovation through clinical research.

Cutera is currently accepting applications from universities and programs interested in joining the Cutera Residency Program. Interested parties can apply and learn more by emailing [email protected].

For further information on Cutera and AviClear please visit www.cutera.com.

About Cutera, Inc.
Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera strives to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1-888-4-CUTERA or visit Cutera.com.

AviClear Important Safety Information:

Indications for Use: AviClear is FDA-cleared for the long-term treatment of mild to severe inflammatory acne vulgaris.

Contraindications: Pregnant patients and patients undergoing treatment for skin cancer.

Important Safety Information: The following treatment-related side effects may occur during or after treatment with AviClear: Discomfort, erythema and edema, transient acne flareups, temporary skin dryness, blisters, crusting/scabbing, hyperpigmentation, skin texture changes, infection, scarring, hypopigmentation and altered hair growth.

Warnings: Do not treat over dysplastic nevi or questionable pigmented lesions; do not treat over or close to tattoos or permanent make-up.

Precautions: Use only topical anesthetics recommended by Cutera for AviClear treatments. Use caution when treating patients with any of the following: current or recent use of Isotretinoin (Accutane/Roaccutane), current or recent use of anticoagulants, presence of any inflammatory skin condition other than acne in the target area, history of malignant tumors in the target area, history of coagulopathies, history of keloids or hypertrophic scarring, history of vitiligo or pigmentary disorders, history of herpes - pre-treatment with an antiviral may be indicated, open lesions or wounds - treatment should only be performed on intact skin, metal or electronic implants - reaction to treating over implants is unknown; check with implant manufacturer or physician managing the implant before treating. The AviClear Laser System has not been studied on the lips, upper and lower eyelids, and eyebrows. Refer to the Operator Manual to view the laser safety labels of the product.

Media Contacts: EvolveMKD [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/cutera-launches-new-residency-program-to-shape-the-future-of-dermatology-302566080.html

SOURCE Cutera